+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
MALE
ID07611110

Evaluating AZD2265 Versus Standard Treatments in Men with PSMA-positive Metastatic Castration-resistant Prostate Cancer VECTRA-01

Led by AstraZeneca · Updated on 2026-10-19

670

Participants Needed

151

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of AZD2265 compared to standard treatments in men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC. The study aims to show whether AZD2265 can improve radiographic progression-free survival and overall survival. This phase III trial involves about 670 adult male participants and is sponsored by AstraZeneca. Participants will be randomly assigned to receive either AZD2265 or a standard care treatment chosen by the investigator, which may include cabazitaxel, androgen receptor pathway inhibitors ARPI, or radium-223. Treatments will continue until the disease progresses, unacceptable side effects occur, or other reasons for stopping arise. Tumor scans will continue after treatment ends until confirmed progression or death. Throughout the study, participants will be monitored with imaging scans and laboratory tests to assess disease progression and response to treatment. Researchers will track multiple outcomes such as progression-free survival, PSA reductions, response rates, and symptomatic skeletal events for up to approximately 33 months. Safety and scientific integrity will be overseen by an independent committee, and participants will be followed for survival until the studys completion.

CONDITIONS

Brief Title

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here